Notícias Acurx Pharmaceuticals Inc - ACXP | Ações NASDAQ

Monitor
Book
Fórum
Rankings
Portfolio
Mundo
Trader Chat
Scanner
Mais

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.

AI Entrar

Premium

Suporte
(11) 4950 5808
suporte@advfn.com.br
Fale Conosco

Início
Investir
Ações
EUA
NASDAQ
Acurx Pharmaceuticals Inc (ACXP)
Acurx Pharmaceuticals Inc (ACXP) Notícias

Acurx Pharmaceuticals Inc (ACXP)

0,78

0,0499

(6,83%)

Fechado 04 Fevereiro 6:00PM

Atrasado por 15 minutos

0,78

0,00

( 0,00% )

Pré-mercado: 6:00AM

Atrasado por 15 minutos

NASDAQ

ACXP

Acurx Pharmaceuticals

Gráfico
Book
Fórum
Negócios
Notícias
Balanços

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

Acurx Pharmaceuticals Inc (ACXP)

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Notícias de ACXP

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Form 424B3 - Prospectus [Rule 424(b)(3)]

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Fóruns

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

Tendências Agora

Rankings

Dados

Notícias

Ferramentas

Mercados

Comunidade

Recursos principais

Follow Feed

Fluxo de Opções

Monitor

Acurx Pharmaceuticals Inc (ACXP) Notícias

Acurx Pharmaceuticals Inc (ACXP)

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Notícias de ACXP

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Form 424B3 - Prospectus [Rule 424(b)(3)]

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Form 8-K - Current report

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Fóruns

Seu Histórico Recente

Empresa

Negócios

Popular

Obter o aplicativo

Vá sem anúncios